Concepedia

Author

Ike Ogbaa

Lexicon Pharmaceuticals (United States)

Also Known As

I Ogbaa, IKE OGBAA, Ike Ogbaa

17

Publications

406

Citations

8

H-Index

11

Concepts

All Affiliations

Lexicon Pharmaceuticals (United States)Dallas Diabetes Research CenterPennington Biomedical Research Center
IO

About

Ike Ogbaa is an author at Lexicon Pharmaceuticals (United States) specializing in metabolic syndrome, diabetes, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

191

2

Diabetes

3

3

191

3

Health Sciences

2

2

142

4

Pharmacology

2

2

142

5

Nephrology

1

1

49

Ike Ogbaa

×

7

Publications

357

Citations

7

H-Index

YearCitations

Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy

Julio Rosenstock, William T. Cefalu, Pablo Lapuerta,

Diabetes Care

2014

78

Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes

Brian Zambrowicz, Zhi‐Ming Ding, Ike Ogbaa,

Clinical Therapeutics

2013

77

Effects of LX4211, a Dual Sodium-Dependent Glucose Cotransporters 1 and 2 Inhibitor, on Postprandial Glucose, Insulin, Glucagon-like Peptide 1, and Peptide Tyrosine Tyrosine in a Dose-Timing Study in Healthy Subjects

Brian Zambrowicz, Ike Ogbaa, Kenny Frazier,

Clinical Therapeutics

2013

65

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results

Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos,

Nephrology Dialysis Transplantation

2021

60

LX4211 Therapy Reduces Postprandial Glucose Levels in Patients With Type 2 Diabetes Mellitus and Renal Impairment Despite Low Urinary Glucose Excretion

Brian Zambrowicz, Pablo Lapuerta, Paul Strumph,

Clinical Therapeutics

2014

49

Study Design and Rationale of a Dose‐Ranging Trial of <scp>LX4211</scp>, a Dual Inhibitor of <scp>SGLT1</scp> and <scp>SGLT2</scp>, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy

Pablo Lapuerta, Julio Rosenstock, Brian Zambrowicz,

Clinical Cardiology

2013

14

Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study

Marcus Hompesch, Jahoon Kang, Oakpil Han,

BMJ Open Diabetes Research & Care

2021

14

Page 1